Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,inventory,accountsPayable,goodWill,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,dividendsPaid,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,repurchaseOfStock,changeToInventory,changeToAccountReceivables,investments,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,currency,priceHint,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,fax,industry
t0,HLUYY,-5910000000.0,198698000,917000000,,797000000,,621000000,1528000000,3327000000,882000000,882000000,,-37000000,,,,176000000,4273000000,3391000000,946000000,-85000000,,621000000,621000000,23133000000.0,17242000000.0,17223000000.0,3816000000.0,34465000000.0,996000000.0,15896000000.0,3526000000.0,331000000.0,385000000.0,1661000000.0,7964000000.0,266000000.0,400000000.0,331000000.0,2758000000.0,8107000000.0,82000000.0,3864000000.0,5314000000.0,2582000000.0,3667000000.0,,0.0,-84000000.0,-1752000000.0,-2303000000.0,-915000000.0,-2263000000.0,16000000.0,108000000.0,470000000.0,-497000000.0,-54000000.0,-68000000.0,-84000000.0,,,,,143000000.0,en-US,US,EQUITY,False,Delayed Quote,1.6385092,30.075 - 30.11,29.6,0.0,0.0,0,0,finmb_671670,Other OTC,H. Lundbeck A/S,DKK,2640,1985,2.3849983,0.08610102,27.7 - 43.05,-12.965,-0.30116144,27.7,43.05,1617321600,2.5,17.655516,0.08445946,1.704,USD,2,86.678,30.213715,-0.12871552,-0.0042601684,32.91058,-2.8255806,-0.085856296,5977829376,0.3470892,15,America/New_York,EDT,-14400000,PNK,0,False,False,30.085,1630509354,0.4849987,30.075,30.11,30.075,990,H.LUNDBECK A/S,us_market,PRE,0.62,,,43.05,27.7,30.21,32.91,2.64k,1.99k,198.7M,,61.21M,0.00%,0.08%,,,,,,0.4,1.27%,2.50,8.45%,,23.67%,"Apr 01, 2021","Mar 23, 2021",,,"Dec 30, 2020","Mar 30, 2021",12.14%,20.45%,6.41%,13.48%,17.38B,87.47,-6.40%,13.55B,4.77B,2.11B,1.70,575.00%,1.66B,8.36,6.23B,36.18,1.02,86.68,3.76B,2.61B,Value,2500,Healthcare,5551,2,1,"H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.",Valby,45 36 30 13 11,1,1609372800,1625097600,3,Denmark,http://www.lundbeck.com,86400,1,Ottiliavej 9,45 36 30 19 40,Drug Manufacturers—Specialty & Generic
t-1,HLUYY,-5765000000.0,198698000,883000000,,192000000,,376000000,1932000000,2894000000,79000000,79000000,,-41000000,,,,-184000000,4275000000,4196000000,1381000000,113000000,,376000000,376000000,17893000000.0,19056000000.0,16973000000.0,3191000000.0,36029000000.0,996000000.0,15748000000.0,3231000000.0,229000000.0,829000000.0,3924000000.0,10012000000.0,233000000.0,2000000000.0,229000000.0,2241000000.0,10105000000.0,116000000.0,3638000000.0,5397000000.0,2163000000.0,3740000000.0,4845000000.0,0.0,-211000000.0,-678000000.0,-615000000.0,1007000000.0,221000000.0,-13000000.0,1060000000.0,-2000000.0,-497000000.0,92000000.0,372000000.0,-98000000.0,-29000000.0,-265000000.0,-428000000.0,,93000000.0,en-US,US,EQUITY,False,Delayed Quote,1.6385092,30.075 - 30.11,29.6,0.0,0.0,0,0,finmb_671670,Other OTC,H. Lundbeck A/S,DKK,2640,1985,2.3849983,0.08610102,27.7 - 43.05,-12.965,-0.30116144,27.7,43.05,1617321600,2.5,17.655516,0.08445946,1.704,USD,2,86.678,30.213715,-0.12871552,-0.0042601684,32.91058,-2.8255806,-0.085856296,5977829376,0.3470892,15,America/New_York,EDT,-14400000,PNK,0,False,False,30.085,1630509354,0.4849987,30.075,30.11,30.075,990,H.LUNDBECK A/S,us_market,PRE,0.62,,,43.05,27.7,30.21,32.91,2.64k,1.99k,198.7M,,61.21M,0.00%,0.08%,,,,,,0.4,1.27%,2.50,8.45%,,23.67%,"Apr 01, 2021","Mar 23, 2021",,,"Dec 30, 2020","Mar 30, 2021",12.14%,20.45%,6.41%,13.48%,17.38B,87.47,-6.40%,13.55B,4.77B,2.11B,1.70,575.00%,1.66B,8.36,6.23B,36.18,1.02,86.68,3.76B,2.61B,Value,2500,Healthcare,5551,2,1,"H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.",Valby,45 36 30 13 11,1,1609372800,1625097600,3,Denmark,http://www.lundbeck.com,86400,1,Ottiliavej 9,45 36 30 19 40,Drug Manufacturers—Specialty & Generic
t-2,HLUYY,-6327000000.0,198698000,951000000,,629000000,,472000000,1611000000,3448000000,886000000,886000000,,-140000000,,,,157000000,4463000000,3577000000,1015000000,-257000000,,472000000,472000000,21002000000.0,19915000000.0,14675000000.0,4314000000.0,34590000000.0,996000000.0,13137000000.0,2106000000.0,542000000.0,,3703000000.0,8104000000.0,,215000000.0,542000000.0,2652000000.0,9865000000.0,1071000000.0,3957000000.0,9705000000.0,2205000000.0,3575000000.0,,0.0,-140000000.0,-532000000.0,-552000000.0,183000000.0,462000000.0,-28000000.0,1182000000.0,444000000.0,-497000000.0,-20000000.0,83000000.0,-127000000.0,-29000000.0,-265000000.0,-428000000.0,-13000000.0,1761000000.0,en-US,US,EQUITY,False,Delayed Quote,1.6385092,30.075 - 30.11,29.6,0.0,0.0,0,0,finmb_671670,Other OTC,H. Lundbeck A/S,DKK,2640,1985,2.3849983,0.08610102,27.7 - 43.05,-12.965,-0.30116144,27.7,43.05,1617321600,2.5,17.655516,0.08445946,1.704,USD,2,86.678,30.213715,-0.12871552,-0.0042601684,32.91058,-2.8255806,-0.085856296,5977829376,0.3470892,15,America/New_York,EDT,-14400000,PNK,0,False,False,30.085,1630509354,0.4849987,30.075,30.11,30.075,990,H.LUNDBECK A/S,us_market,PRE,0.62,,,43.05,27.7,30.21,32.91,2.64k,1.99k,198.7M,,61.21M,0.00%,0.08%,,,,,,0.4,1.27%,2.50,8.45%,,23.67%,"Apr 01, 2021","Mar 23, 2021",,,"Dec 30, 2020","Mar 30, 2021",12.14%,20.45%,6.41%,13.48%,17.38B,87.47,-6.40%,13.55B,4.77B,2.11B,1.70,575.00%,1.66B,8.36,6.23B,36.18,1.02,86.68,3.76B,2.61B,Value,2500,Healthcare,5551,2,1,"H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.",Valby,45 36 30 13 11,1,1609372800,1625097600,3,Denmark,http://www.lundbeck.com,86400,1,Ottiliavej 9,45 36 30 19 40,Drug Manufacturers—Specialty & Generic
t-3,HLUYY,-7463000000.0,198698000,1040000000,,844000000,,582000000,1649000000,3452000000,763000000,763000000,,-140000000,,,,262000000,4370000000,3607000000,918000000,81000000,,582000000,582000000,21955000000.0,20598000000.0,14492000000.0,4394000000.0,35090000000.0,996000000.0,12658000000.0,2147000000.0,838000000.0,,3241000000.0,8062000000.0,,76000000.0,838000000.0,2637000000.0,9408000000.0,1090000000.0,3734000000.0,10389000000.0,2433000000.0,3592000000.0,,0.0,-48000000.0,-341000000.0,-391000000.0,457000000.0,958000000.0,-10000000.0,1407000000.0,593000000.0,-497000000.0,-50000000.0,-225000000.0,-71000000.0,-29000000.0,-265000000.0,-428000000.0,23000000.0,1346000000.0,en-US,US,EQUITY,False,Delayed Quote,1.6385092,30.075 - 30.11,29.6,0.0,0.0,0,0,finmb_671670,Other OTC,H. Lundbeck A/S,DKK,2640,1985,2.3849983,0.08610102,27.7 - 43.05,-12.965,-0.30116144,27.7,43.05,1617321600,2.5,17.655516,0.08445946,1.704,USD,2,86.678,30.213715,-0.12871552,-0.0042601684,32.91058,-2.8255806,-0.085856296,5977829376,0.3470892,15,America/New_York,EDT,-14400000,PNK,0,False,False,30.085,1630509354,0.4849987,30.075,30.11,30.075,990,H.LUNDBECK A/S,us_market,PRE,0.62,,,43.05,27.7,30.21,32.91,2.64k,1.99k,198.7M,,61.21M,0.00%,0.08%,,,,,,0.4,1.27%,2.50,8.45%,,23.67%,"Apr 01, 2021","Mar 23, 2021",,,"Dec 30, 2020","Mar 30, 2021",12.14%,20.45%,6.41%,13.48%,17.38B,87.47,-6.40%,13.55B,4.77B,2.11B,1.70,575.00%,1.66B,8.36,6.23B,36.18,1.02,86.68,3.76B,2.61B,Value,2500,Healthcare,5551,2,1,"H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.",Valby,45 36 30 13 11,1,1609372800,1625097600,3,Denmark,http://www.lundbeck.com,86400,1,Ottiliavej 9,45 36 30 19 40,Drug Manufacturers—Specialty & Generic
